Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$0.90 USD
0.00 (0.43%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $0.91 +0.02 (1.68%) 6:14 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTSO 0.90 0.00(0.43%)
Will CTSO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CTSO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTSO
CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates
CytoSorbents (CTSO) Reports Q2 Loss, Lags Revenue Estimates
CTSO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Other News for CTSO
Here's the major earnings after the close today
Cytosorbents GAAP EPS of -$0.08 beats by $0.02, revenue of $9.9M beats by $0.22M
CytoSorbents appoints Peter Mariani as Chief Financial Officer
CytoSorbents reports Q2 EPS (8c), consensus (10c)
CytoSorbents appoints Peter J. Mariani as CFO